Atea anticipates top line Phase III HCV results midyear 2026 while advancing HEV program
Source: SeekingAlpha
2026-03-05 18:57:06 ET
More on Atea Pharmaceuticals
- Atea Pharmaceuticals, Inc. 2025 Q4 - Results - Earnings Call Presentation
- Atea Pharmaceuticals, Inc. (AVIR) Q4 2025 Earnings Call Transcript
- Atea Pharmaceuticals, Inc. (AVIR) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
- Seeking Alpha’s Quant Rating on Atea Pharmaceuticals
- Historical earnings data for Atea Pharmaceuticals
Read the full article on Seeking Alpha
For further details see:
Atea anticipates top line Phase III HCV results midyear 2026 while advancing HEV program
Atea Pharmaceuticals Inc.
NASDAQ: AVIR
AVIR Trading
3.92% G/L:
$6.355 Last:
427,987 Volume:
$6.13 Open:
AVIR Latest News
March 05, 2026 04:05:00 pm
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
AVIR Stock Data
$327,351,275
63,985,846
0.97%
32
N/A
Biotechnology & Life Sciences
Healthcare
US
Boston
